Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fawaz Abdrabbo

Psychiatry Ridgeland, MS Medical Doctor

NPI 1760466551 CMS profile 79394

625 Highland Colony Pkwy, Suite 101, Ridgeland, MS 39157

Open in the dashboard

General payments

$4,360

249 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fawaz Abdrabbo of Ridgeland, MS is reported in the CMS Open Payments database as having received $4,360 across 249 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $467 24
2024 General $556 30
2023 General $693 37
2022 General $902 51
2021 General $1,086 61
2020 General $293 19
2019 General $362 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fawaz Abdrabbo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Fawaz Abdrabbo were reported at $467. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Fawaz Abdrabbo Psychiatry median Middle half National median
2019 $362 $184 $59–$605 $163
2020 $293 $119 $36–$372 $114
2021 $1,086 $143 $43–$576 $132
2022 $902 $153 $50–$590 $149
2023 $693 $170 $56–$651 $160
2024 $556 $179 $57–$673 $164
2025 $467 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,194 76 payments
  2. Otsuka America Pharmaceutical, Inc. $646 33 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $527 33 payments
  4. Axsome Therapeutics, Inc. $302 12 payments
  5. Lundbeck LLC $283 14 payments
  6. Allergan Inc. $219 20 payments
  7. Eisai Inc. $152 10 payments
  8. Vanda Pharmaceuticals Inc. $127 6 payments
  9. Supernus Pharmaceuticals, Inc. $115 8 payments
  10. Teva Pharmaceuticals USA, Inc. $115 5 payments
  11. Other $682 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,360 249 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,018 65 payments
  2. REXULTI Psychiatry $646 33 payments
  3. TRINTELLIX $508 31 payments
  4. VRAYLAR Neuroscience $395 31 payments
  5. REXULTI Psychiatry $216 11 payments
  6. Sunosi $212 7 payments
  7. Dayvigo $152 10 payments
  8. FANAPT $127 6 payments
  9. QUVIVIQ $110 2 payments
  10. HETLIOZ $99 5 payments
  11. Other $964 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

413

Median for Psychiatry & Neurology: 100

Drug cost

$5,430

Median for Psychiatry & Neurology: $2,986

Branded share of claims

14%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluvoxamine Maleate Generic 25 $1,010
Alprazolam Er Alprazolam Brand 25 $638
Venlafaxine Hcl Er Venlafaxine Hcl Brand 33 $527
Carbamazepine Generic 22 $491
Eszopiclone Generic 14 $403
Aripiprazole Generic 17 $343
Trazodone Hcl Generic 39 $321
Sertraline Hcl Generic 50 $285
Lamotrigine Generic 20 $276
Oxcarbazepine Generic 13 $263

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $189
$189 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $66
  • Lundbeck LLC $54
$119 — —
Sunosi
  • Axsome Therapeutics, Inc. $116
$116 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $56
$56 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record